Chau T N, Lai S T, Lai J Y, Yuen H
Department of Medicine, Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong, PRC.
Scand J Infect Dis. 1997;29(6):551-3. doi: 10.3109/00365549709035892.
Haemolytic anaemia as a complication of acute hepatitis has been reported in up to 23% of patients. However, the incidence may rise up to 70-87% in patients who have glucose-6-phosphate dehydrogenase (G6PD) deficiency. Massive intravascular haemolysis with renal failure, hepatic encephalopathy and even death have been reported. In our retrospective study of patients with acute viral hepatitis, the overall incidence of acute haemolysis was 4% (17/434). Only 53% (9/17) of them had G6PD deficiency. Patients with acute haemolysis had a significantly higher peak bilirubin level and required more prolonged hospitalization. Since hepatitis A virus vaccination, unlike hepatitis B virus vaccination, is not yet recommended for routine immunization, we suggest subjects who are G6PD-deficient should be vaccinated against hepatitis A. In endemic areas of hepatitis A virus infection, universal immunization remains the definitive answer.
据报道,急性肝炎的并发症溶血性贫血在高达23%的患者中出现。然而,葡萄糖-6-磷酸脱氢酶(G6PD)缺乏的患者中,这一发病率可能升至70 - 87%。已有报告称出现伴有肾衰竭、肝性脑病甚至死亡的大量血管内溶血。在我们对急性病毒性肝炎患者的回顾性研究中,急性溶血的总体发病率为4%(17/434)。其中只有53%(9/17)的患者存在G6PD缺乏。急性溶血患者的胆红素峰值水平显著更高,且需要更长时间的住院治疗。由于甲型肝炎病毒疫苗接种与乙型肝炎病毒疫苗接种不同,目前尚未建议常规免疫,我们建议G6PD缺乏的受试者接种甲型肝炎疫苗。在甲型肝炎病毒感染的流行地区,普遍免疫仍然是最终的解决办法。